JP2016519932A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519932A5
JP2016519932A5 JP2016513127A JP2016513127A JP2016519932A5 JP 2016519932 A5 JP2016519932 A5 JP 2016519932A5 JP 2016513127 A JP2016513127 A JP 2016513127A JP 2016513127 A JP2016513127 A JP 2016513127A JP 2016519932 A5 JP2016519932 A5 JP 2016519932A5
Authority
JP
Japan
Prior art keywords
cell
human
sortase
antibody
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016513127A
Other languages
English (en)
Other versions
JP6603209B2 (ja
JP2016519932A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/037545 external-priority patent/WO2014183066A2/en
Publication of JP2016519932A publication Critical patent/JP2016519932A/ja
Publication of JP2016519932A5 publication Critical patent/JP2016519932A5/ja
Priority to JP2019079111A priority Critical patent/JP6901154B2/ja
Application granted granted Critical
Publication of JP6603209B2 publication Critical patent/JP6603209B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. ヒト細胞に薬剤を結合させる方法において、ソルターゼの存在下で、ヒト細胞を、ソルターゼ認識配列及び薬剤を含むソルターゼ基質と、前記ソルターゼが前記ソルターゼ基質を前記ヒト細胞により発現された内在性の非操作ポリペプチドと結合させるのに好適な条件下で接触させるステップを含むことを特徴とする方法。
  2. 請求項1に記載の方法において、前記ソルターゼ基質を、前記細胞により発現された内在性の非操作ポリペプチドの細胞外部分に結合させることを特徴とする方法。
  3. 請求項1又は2に記載の方法において、前記ヒト細胞が、免疫系細胞、赤血球又はその前駆細胞であることを特徴とする方法。
  4. 請求項1乃至の何れか1項に記載の方法において、前記ヒト細胞が非不死化細胞であることを特徴とする方法。
  5. 請求項1乃至の何れか1項に記載の方法において、前記薬剤が、アミノ酸、ペプチド、タンパク質、ポリヌクレオチド、炭水化物、タグ、金属原子、キレート剤、造影剤、触媒、ポリマー、認識エレメント、小分子、脂質、標識、エピトープ、抗原、治療薬、架橋剤、毒素、放射性同位体、抗体、抗体ドメイン、クリックケミストリーハンドル、ウイルス、細胞、又は粒子を含むことを特徴とする方法。
  6. 請求項1乃至の何れか1項に記載の方法に従って調製されることを特徴とする単離ヒト細胞又は単離ヒト細胞の集団。
  7. (i)ソルターゼ媒介反応において求核基の役割を果たすことができる配列を含む内在性の非操作ポリペプチドを含むヒト細胞;(ii)ソルターゼ認識モチーフを含むソルターゼ基質;及び(iii)ソルターゼを含むことを特徴とする組成物。
  8. 請求項に記載の組成物において、前記ヒト細胞が、免疫系細胞、赤血球又はその前駆細胞であることを特徴とする組成物。
  9. 請求項7又は8に記載の組成物において、前記ヒト細胞が非不死化細胞であることを特徴とする組成物。
  10. 請求項乃至の何れか1項に記載の組成物において、前記薬剤が、アミノ酸、ペプチド、タンパク質、ポリヌクレオチド、炭水化物、タグ、金属原子、キレート剤、造影剤、触媒、ポリマー、認識エレメント、小分子、脂質、標識、エピトープ、抗原、治療薬、架橋剤、毒素、放射性同位体、抗体、抗体ドメイン、クリックケミストリーハンドル、ウイルス、細胞、又は粒子を含むことを特徴とする組成物。
  11. 結合部分又は治療薬がソルターゼ認識配列を介して連結されたヒト細胞において、前記結合部分又は治療薬が、前記細胞により発現される内在性の非遺伝子操作タンパク質に連結されることを特徴とするヒト細胞。
  12. 請求項11に記載のヒト細胞において、前記細胞が、ソルターゼ認識配列を介して連結された結合部分を有し、前記部分が抗体を含み、任意選択で、前記抗体は、モノクローナル抗体、一本鎖抗体、単一ドメイン抗体であり、さらに任意選択で、前記単一ドメイン抗体は、VHHであることを特徴とするヒト細胞。
  13. 請求項11に記載のヒト細胞において、前記細胞が、ソルターゼ認識配列を介して連結された治療薬を有し、前記治療薬が酵素を含むことを特徴とするヒト細胞。
  14. 請求項11乃至13の何れか1項に記載のヒト細胞において、ヒト細胞が免疫系細胞であるか、又はヒト細胞が赤血球又はその前駆細胞であることを特徴とするヒト細胞。
  15. 請求項11乃至14の何れか1項に記載のヒト細胞であって、疾患の治療が必要な被験者を治療する方法に用いるためのヒト細胞。
JP2016513127A 2013-05-10 2014-05-09 ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾 Active JP6603209B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019079111A JP6901154B2 (ja) 2013-05-10 2019-04-18 ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361822092P 2013-05-10 2013-05-10
US61/822,092 2013-05-10
US201461943094P 2014-02-21 2014-02-21
US61/943,094 2014-02-21
PCT/US2014/037545 WO2014183066A2 (en) 2013-05-10 2014-05-09 Protein modification of living cells using sortase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019079111A Division JP6901154B2 (ja) 2013-05-10 2019-04-18 ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾

Publications (3)

Publication Number Publication Date
JP2016519932A JP2016519932A (ja) 2016-07-11
JP2016519932A5 true JP2016519932A5 (ja) 2017-06-22
JP6603209B2 JP6603209B2 (ja) 2019-11-06

Family

ID=51867884

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016513127A Active JP6603209B2 (ja) 2013-05-10 2014-05-09 ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾
JP2019079111A Active JP6901154B2 (ja) 2013-05-10 2019-04-18 ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾
JP2021043795A Active JP7306731B2 (ja) 2013-05-10 2021-03-17 ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019079111A Active JP6901154B2 (ja) 2013-05-10 2019-04-18 ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾
JP2021043795A Active JP7306731B2 (ja) 2013-05-10 2021-03-17 ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾

Country Status (5)

Country Link
US (3) US10260038B2 (ja)
EP (2) EP4119662A1 (ja)
JP (3) JP6603209B2 (ja)
AU (3) AU2014262469B2 (ja)
WO (1) WO2014183066A2 (ja)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525904A (ja) 2011-06-28 2014-10-02 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ タンパク質連結用クリックケミストリーハンドルを設置するためのソルターゼの使用
JP6603209B2 (ja) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾
EP3546485A1 (en) 2013-05-10 2019-10-02 Whitehead Institute for Biomedical Research In vitro production of red blood cells with sortaggable proteins
WO2015048312A1 (en) * 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
HUE054471T2 (hu) 2014-04-01 2021-09-28 Rubius Therapeutics Inc Immunmodulációs módszerek és készítmények
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
US20170226495A1 (en) * 2014-07-21 2017-08-10 Novartis Ag Sortase molecules and uses thereof
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
GB201417288D0 (en) * 2014-09-30 2014-11-12 Univ Dundee Cysteine labelling
US10053683B2 (en) * 2014-10-03 2018-08-21 Whitehead Institute For Biomedical Research Intercellular labeling of ligand-receptor interactions
WO2016075176A1 (en) * 2014-11-11 2016-05-19 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
JP6800154B2 (ja) 2014-12-17 2020-12-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 結合形成酵素の活性アッセイ
SG11201704627XA (en) 2014-12-17 2017-07-28 Hoffmann La Roche Enzymatic one-pot reaction for double polypeptide conjugation in a single step using sortase
BR112017018770A2 (pt) 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. redução da tolerância imunológica induzida por pd-l1
WO2016179310A1 (en) * 2015-05-04 2016-11-10 Smith Andrew Dennis Computer-assisted tumor response assessment and evaluation of the vascular tumor burden
EP3461337A1 (en) 2015-05-06 2019-04-03 Snipr Technologies Limited Altering microbial populations & modifying microbiota
CA2994965A1 (en) * 2015-08-06 2017-02-09 Memorial Sloan-Kettering Cancer Center Methods and compositions for tumor therapy
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
JP2017043547A (ja) * 2015-08-24 2017-03-02 国立研究開発法人理化学研究所 ポリペプチドを結合した成長因子及びその利用
WO2017050872A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Transamidation employing sortase a in deep eutectic solvents
JP6895953B2 (ja) 2015-09-25 2021-06-30 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ソルターゼaを利用してチオエステルを作製するための方法
EP3353291B1 (en) * 2015-09-25 2021-06-09 F. Hoffmann-La Roche AG Novel soluble sortase a
US20180280551A1 (en) 2015-10-01 2018-10-04 Whitehead Institute For Biomedical Research Labeling of antibodies
AU2016348391A1 (en) * 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses
CN105400773B (zh) * 2015-12-14 2018-06-26 同济大学 应用于大规模筛选癌症基因的CRISPR/Cas9富集测序方法
KR20180095098A (ko) 2016-01-11 2018-08-24 루비우스 테라퓨틱스, 아이엔씨. 암 적응증에 대한 다중양식 치료 세포 시스템과 관련된 조성물 및 방법
CN105821039B (zh) * 2016-03-09 2020-02-07 李旭 联合免疫基因抑制HBV复制的特异性sgRNA、表达载体及其应用
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
AU2017301880C1 (en) * 2016-07-29 2022-04-21 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
EP3500663A1 (en) * 2016-08-29 2019-06-26 PDI Pharm Development International AG Provision of a therapeutically active cell product
WO2018053180A2 (en) 2016-09-14 2018-03-22 The Trustees Of The University Of Pennsylvania Proximity-based sortase-mediated protein purification and ligation
WO2018068201A1 (en) * 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
AU2017347848A1 (en) * 2016-10-27 2019-05-23 Intima Bioscience, Inc. Viral methods of making genetically modified cells
RU2019120400A (ru) 2016-12-02 2021-01-11 Рубиус Терапьютикс, Инк. Композиции и способы, связанные с клеточными системами для проникновения в солидные опухоли
US20190375815A1 (en) * 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018144966A1 (en) * 2017-02-06 2018-08-09 The Board Of Trustees Of The Leland Stanford Junior University Bioconjugation methods for targeted in situ therapeutic delivery
JP2020507329A (ja) 2017-02-17 2020-03-12 ルビウス セラピューティクス, インコーポレイテッド 機能化赤血球系細胞
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US20200172868A1 (en) 2017-07-19 2020-06-04 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for infectious disease
WO2019017937A1 (en) 2017-07-19 2019-01-24 Rubius Therapeutics, Inc. COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIMODAL THERAPEUTIC CELLULAR SYSTEMS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASE
EP4328314A3 (en) 2017-08-22 2024-03-20 Tessera Therapeutics, Inc. Lipid nanoparticle methods and compositions for producing engineered erythroid cells
US20210214724A1 (en) * 2017-10-23 2021-07-15 The Broad Institute, Inc. Novel nucleic acid modifiers
WO2019090148A2 (en) 2017-11-03 2019-05-09 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019133881A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for enginerering erythroid cells
WO2019140116A2 (en) 2018-01-10 2019-07-18 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
SG11202008261WA (en) 2018-03-08 2020-09-29 Rubius Therapeutics Inc Therapeutic cell systems and methods for treating cancer and infectious diseases
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
AU2019257789A1 (en) * 2018-04-27 2020-11-12 Crispr Therapeutics Ag Anti-BCMA CAR-T-cells for plasma cell depletion
CN110499291B (zh) * 2018-05-16 2023-11-24 上海赛比曼生物科技有限公司 无血清培养制备嵌合抗原受体t细胞的方法
RU2677264C1 (ru) * 2018-05-24 2019-01-16 Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") Иммунотоксин для терапии рассеянного склероза, способ его получения и применения
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3818072A1 (en) * 2018-07-03 2021-05-12 Technische Universität München Means and methods for site-specific protein modification using transpeptidases
US20210353769A1 (en) * 2018-09-21 2021-11-18 City University Of Hong Kong Surface modified extracellular vesicles
EP3864143A4 (en) * 2018-10-12 2022-08-17 The Trustees of The University of Pennsylvania COMPOSITIONS AND METHODS FOR SWITCHABLE CAR-T CELLS USING SURFACE-BOND SORTASE TRANSPEPTIDASE
US20220023430A1 (en) * 2018-11-13 2022-01-27 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
US20200172597A1 (en) 2018-12-03 2020-06-04 Rubius Therapeutics, Inc. Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use
WO2020172472A1 (en) 2019-02-20 2020-08-27 Rubius Therapeutics, Inc. Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
WO2020220016A1 (en) * 2019-04-26 2020-10-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy
AU2020263513A1 (en) 2019-04-26 2021-11-18 Rubius Therapeutics, Inc. Buffered compositions including enucleated erythroid cells
JP2022533702A (ja) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド MAdCAM標的化免疫寛容
CA3141315A1 (en) 2019-05-24 2020-12-03 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
CA3160464A1 (en) 2019-11-04 2021-05-14 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using taurine or hypotaurine
JP2023500327A (ja) 2019-11-04 2023-01-05 ルビウス セラピューティクス, インコーポレイテッド ミオイノシトールを使用して除核赤芽球細胞を生成する方法
CA3164176A1 (en) 2020-01-13 2021-07-22 Carmine Therapeutics Pte. Ltd. Nucleic acid loaded red blood cell extracellular vesicles
US20210246426A1 (en) 2020-02-10 2021-08-12 Rubius Therapeutics, Inc. Engineered Erythroid Cells Including HLA-G Polypeptides and Methods of Use Thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021185359A1 (en) * 2020-03-20 2021-09-23 Westlake Therapeutics (Hangzhou) Co. Limited Modified red blood cells and uses thereof for delivering agents
WO2021228832A1 (en) 2020-05-11 2021-11-18 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
USD980069S1 (en) 2020-07-14 2023-03-07 Ball Corporation Metallic dispensing lid
CN111848816B (zh) * 2020-07-24 2021-06-08 斯普迈(北京)生物科技有限公司 融合蛋白及其用途
WO2022089605A1 (en) * 2020-10-30 2022-05-05 Westlake Therapeutics (Hangzhou) Co. Limited Modified red blood cells and uses thereof for delivering agents
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
TW202241471A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 提高個體中NKp30陽性淋巴球的方法及其用途
WO2022150578A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. Methods of treating a tumor in a human subject
WO2022160156A1 (en) 2021-01-28 2022-08-04 Genequantum Healthcare (Suzhou) Co., Ltd. Ligase fusion proteins and applications thereof
TW202304482A (zh) 2021-03-14 2023-02-01 美商盧比亞斯治療公司 於個體中增加nkg2d陽性淋巴球之方法及其用途
JP2024511839A (ja) 2021-03-31 2024-03-15 カーマイン・セラピューティクス・プライベート・リミテッド 少なくとも2つの異なる核酸を担持した細胞外小胞
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療hpv16-陽性或hpv16-相關的癌症之方法
CN117730143A (zh) * 2021-07-13 2024-03-19 西湖生物医药科技(杭州)有限公司 通过缀合的n-末端甘氨酸修饰的细胞及其用途
WO2023108073A2 (en) * 2021-12-10 2023-06-15 Georgiamune Llc Polypeptide modulators
WO2023134573A1 (en) * 2022-01-12 2023-07-20 Westlake Therapeutics (Shanghai) Co., Limited Modified cells and uses thereof
WO2024067295A1 (zh) * 2022-09-28 2024-04-04 西湖生物医药科技(杭州)有限公司 修饰的红细胞及其用于递送药物的用途

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
JP2003506011A (ja) 1999-04-15 2003-02-18 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア ソーターゼ遺伝子の同定
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
EP1311301A2 (en) 2000-07-06 2003-05-21 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
ATE437221T1 (de) 2001-05-14 2009-08-15 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
AU2003268546A1 (en) 2002-09-06 2004-03-29 Massachusetts Institute Of Technology Lentiviral vectors, related reagents, and methods of use thereof
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
US6960473B2 (en) 2003-02-27 2005-11-01 Istituto Superiore Di Sanita In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients
JP2007521234A (ja) 2003-08-12 2007-08-02 ウィリアム エム ヤーブロー 尋常性ざ瘡の治療薬及び使用方法
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
JP5139799B2 (ja) 2004-06-04 2013-02-06 ユニベルシテ ピエール エ マリー キュリー(パリ シズエム) 赤血球細胞の生産方法
US7767453B2 (en) 2004-10-20 2010-08-03 Whitehead Institute For Biomedical Research Cultured hematopoietic stem cells and method for expansion and analysis thereof
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
US7807464B2 (en) 2005-05-24 2010-10-05 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
EP1739165A1 (en) 2005-06-29 2007-01-03 Cellution Biotech B.V. Method and apparatus for cultivating cells utilizing wave motion
US20110142873A1 (en) 2006-05-31 2011-06-16 Gerry Rowse Bioactive purified hspe7 compositions
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
WO2008137641A2 (en) 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
US8282942B2 (en) 2007-10-29 2012-10-09 Trustees Of Dartmouth College Toxoplasma gondii vaccines and uses thereof
US9757440B2 (en) 2007-10-29 2017-09-12 Trustees Of Dartmouth College Method for treating cancer with Toxoplasma gondii vaccine
US20110038888A1 (en) 2008-01-10 2011-02-17 Peter Emtage Adjuvant compositions comprising poly-ic and a cationic polymer
CN102015997B (zh) 2008-05-05 2016-08-10 威尔森沃尔夫制造公司 细胞容器
EP2297295A4 (en) 2008-07-08 2013-11-27 Wolf Wilson Mfg Corp IMPROVED DEVICE FOR CELL CULTURE PERMEABLE TO GAS AND METHOD OF USE
US20120034156A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CA2734908A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
ES2961498T3 (es) 2008-08-26 2024-03-12 Hope City Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
CN102264762B (zh) 2008-09-26 2018-03-27 达纳-法伯癌症研究公司 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用
JP2010115136A (ja) 2008-11-12 2010-05-27 Teruyuki Nagamune N末端標識膜蛋白質の作製方法、及びn末端標識膜蛋白質を表層に有する細胞
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2411507B1 (en) 2009-03-26 2019-09-25 CellProtect Nordic Pharmaceuticals AB Expansion of nk cells
DK2470644T3 (en) 2009-08-24 2017-01-16 Baylor College Medicine GENERATION OF CTL LINES WITH SPECIFICITY AGAINST MORE TUMOR ANTIGEN OR MORE
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US20110151551A1 (en) 2009-12-22 2011-06-23 Ge Healthcare Bio-Sciences Corp. Bioreactors
JP6137596B2 (ja) 2010-02-08 2017-05-31 サンガモ セラピューティクス, インコーポレイテッド 遺伝子操作された切断ハーフドメイン
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
WO2011101468A1 (en) 2010-02-22 2011-08-25 Université Pierre Et Marie Curie (Paris 6) Cell culture medium for the growth and differentiation of cells of the hematopoietic lineage
WO2011104382A1 (en) 2010-02-26 2011-09-01 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
US8802438B2 (en) 2010-04-16 2014-08-12 Children's Medical Center Corporation Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs
US20130122043A1 (en) 2010-04-20 2013-05-16 Whitehead Institute For Biomedical Research Modified polypeptides and proteins and uses thereof
DK2614077T3 (en) 2010-09-08 2016-11-21 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
BR122021026169B1 (pt) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania Uso de uma célula
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
JP2014525904A (ja) 2011-06-28 2014-10-02 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ タンパク質連結用クリックケミストリーハンドルを設置するためのソルターゼの使用
EP2546329A1 (en) 2011-07-11 2013-01-16 Lonza Cologne GmbH Scale up of cell cultures
CN102559600A (zh) * 2011-12-29 2012-07-11 上海交通大学医学院 一种人工抗原递呈细胞及其在nk细胞扩增中的应用
EP2822957A1 (en) 2012-03-07 2015-01-14 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
AU2013245645A1 (en) 2012-04-13 2014-11-13 Whitehead Institute For Biomedical Research Sortase- modified VHH domains and uses thereof
US20140030697A1 (en) 2012-06-14 2014-01-30 Massachusetts Institute Of Technology Sortase-mediated modification of viral surface proteins
US9267127B2 (en) 2012-06-21 2016-02-23 President And Fellows Of Harvard College Evolution of bond-forming enzymes
US9511350B2 (en) 2013-05-10 2016-12-06 Clean Diesel Technologies, Inc. (Cdti) ZPGM Diesel Oxidation Catalysts and methods of making and using same
JP6603209B2 (ja) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルターゼ(Sortase)を用いた生存細胞のタンパク質修飾
EP3546485A1 (en) 2013-05-10 2019-10-02 Whitehead Institute for Biomedical Research In vitro production of red blood cells with sortaggable proteins
WO2015051188A1 (en) 2013-10-02 2015-04-09 Washington University Heterocyclic molecules for biomedical imaging and therapeutic applications
US9878045B2 (en) 2013-10-15 2018-01-30 Regents Of The University Of Minnesota Triorthogonal reagents for dual protein conjugation
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
US10053683B2 (en) 2014-10-03 2018-08-21 Whitehead Institute For Biomedical Research Intercellular labeling of ligand-receptor interactions
US20180280551A1 (en) 2015-10-01 2018-10-04 Whitehead Institute For Biomedical Research Labeling of antibodies
CA3141315A1 (en) 2019-05-24 2020-12-03 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells

Similar Documents

Publication Publication Date Title
JP2016519932A5 (ja)
HRP20201770T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
JP2012143232A5 (ja)
JP2019522490A5 (ja)
NZ701444A (en) Antibodies to matrix metalloproteinase 9
JP2020516603A5 (ja)
RU2021124437A (ru) Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
JP2014502253A5 (ja)
HRP20192262T1 (hr) Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
RU2015146419A (ru) Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl
HRP20220918T1 (hr) Anti-transtiretinska antitijela
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
JP2017529870A5 (ja)
PH12018502451A1 (en) Brain delivery protein
EA201290671A1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
Soshee et al. General in vitro method to analyze the interactions of synthetic polymers with human antibody repertoires
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
JP2018507254A5 (ja)
da Rocha et al. Development of IgY antibodies against anti-snake toxins endowed with highly lethal neutralizing activity
JP2014528696A5 (ja)
JP2016529213A5 (ja)
EA201100741A1 (ru) Антитела к модифицированным пептидам ифр-1/е человека
Yu et al. Method for studying immunoglobulin G binding on hydrophobic surfaces
JP2012523221A5 (ja)
HRP20211753T1 (hr) Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova